Casellas Alberto 4
4 · Synchrony Financial · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Synchrony (SYF) EVP Alberto Casellas Sells Shares, Exercises Options
What Happened
Alberto Casellas, EVP & CEO — Health & Wellness at Synchrony Financial (SYF), sold 41,514 shares in an open-market transaction for $70.60 each, generating $2,930,888 on Feb 17, 2026. On the same date he exercised 5,794 stock option shares at $34.30 ($198,734 in exercise price) and received awards amounting to 208 shares (valued at $15,040). The filing also reports small dividend-equivalent and phantom-unit entries related to restricted stock units and the deferred compensation plan.
Key Details
- Primary sale: 41,514 shares at $70.60, proceeds $2,930,888 (Feb 17, 2026). Transaction code: S (sale).
- Option exercise: 5,794 shares exercised at $34.30, exercise cost $198,734. Transaction code: M (exercise/conversion).
- Awards/settlements: 208 shares awarded at $72.31 (A); 0.76 dividend-equivalent phantom units reported (A, no cash value reported).
- The filing shows a corresponding reported disposal of 5,794 shares (M) with $0 proceeds (reported as derivative settlement).
- Notable footnotes: F2 — the sale was made under a Rule 10b5-1 trading plan adopted Oct 27, 2025; F1 — dividend equivalent units tied to RSUs; F3 — phantom stock units from the Deferred Compensation Plan settle in cash after separation; F4 — the exercised options stem from a 2017 grant.
- Shares owned after the transactions: not specified in the provided filing details.
- Timeliness: Report filed Feb 19, 2026 for Feb 17 transactions (filed within the normal Form 4 timeframe).
Context
This filing combines an options exercise and an open-market sale on the same date. The reporting shows exercised option shares and a same-number derivative disposal reported separately, and the large open-market sale was executed under a pre-established 10b5-1 plan (see F2). Awards and dividend-equivalent/phantom units reflect routine compensation and deferred-compensation mechanics rather than an outright cash purchase. As always, these insider transactions are factual disclosures and do not by themselves indicate the insider’s personal view of the company’s future performance.
Insider Transaction Report
- Award
Dividend Equivalent Unit
[F1]2026-02-17$72.31/sh+208$15,040→ 93,058 total - Exercise/Conversion
Common Stock
[F2]2026-02-17$34.30/sh+5,794$198,734→ 98,852 total - Sale
Common Stock
[F2]2026-02-17$70.60/sh−41,514$2,930,888→ 57,338 total - Award
Phantom Stock Units
[F3]2026-02-17+0.76→ 184.89 total→ Common Stock (0.76 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F2][F4]2026-02-17−5,794→ 5,794 totalExercise: $34.30Exp: 2027-04-01→ Common Stock (5,794 underlying)
Footnotes (4)
- [F1]Represents dividend equivalent units accrued on February 17, 2026 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.
- [F2]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 27, 2025.
- [F3]The reported phantom stock units were acquired pursuant to a dividend reinvestment feature under the Synchrony Financial Deferred Compensation Plan (the "Deferred Compensation Plan") and are to be settled, in cash, six months following the Reporting Person's separation from service to the Company, subject to the requirements set forth in the Deferred Compensation Plan. Each phantom stock unit is the economic equivalent of one share of Synchrony Financial common stock.
- [F4]The reporting person was awarded 11,588 employee stock options on April 1, 2017, which vested in five equal annual installments of 20% each, beginning on the first anniversary of the grant date.